Introduction
The Global Project on Anti-Tuberculosis Drug Resistance Surveillance was initiated in 1994 to estimate the burden of drug-resistant tuberculosis worldwide. The project's primary aims are to monitor trends in resistance and estimate the prevalence of multidrug-resistant (MDR) tuberculosis. Countries that participate in the project follow standardised guidelines for data collection to ensure comparability both between and within countries. The report is published approximately every 3 years since most countries need around 18 months to complete a drug resistance survey.
Until 2000, few national tuberculosis programmes were diagnosing and managing drug-resistant tubercu losis cases in the public sector, with the exception of high-income countries and countries of the former Soviet Union. After the successful implementation of pilot projects to manage drug-resistant tuberculosis, the new Stop TB Strategywhich expands on the directly observed treat ment, shortcourse strategy (DOTS)-was launched in 2006. The Stop TB Strategy includes the diagnosis and management of drug-resistant tuberculosis as one of its components and underpins the Second Global Plan to Stop TB 2006 -2015 , which provides targets and fi nancial estimates for scale-up of the strategy.
1 Nowadays, with the support of the Green Light Committee and other technical and fi nancial partners, many countries are initiating or expanding the diagnosis and management of drug-resistant tuberculosis.
This report provides the latest data on the extent of antituberculosis drug resistance in 83 countries and territories gathered between 2002 and 2007, including the magnitude of extensively drug-resistant (XDR) tuberculosis, 2 and an analysis of the association between HIV and drug-resistant tuberculosis. Data gathered since 1994, from 115 countries, are used to explore trends in resistance. On the basis of such empirical information, new estimates of the global and regional burden of MDR tuberculosis are presented.
Methods

Data collection
A detailed description of the methods of the Global Project can be found in the full report and surveillance guidelines. [3] [4] [5] [6] Briefl y, the surveys are done on the basis of three main principles: the sample of tuberculosis patients must be representative of all cases of tuberculosis in the geographical setting under assessment; drug resistance must be distinguished according to the treatment history of the patient (ie, never treated or previously treated); and laboratory results must be quality assured by a supranational tuberculosis reference laboratory. 7 New cases are defi ned as patients with tuberculosis who have never been treated with antituberculosis drugs or have received them for less than 1 month. Previously treated cases are defi ned as patients who have been treated for tuberculosis for 1 month or more. All newly registered patients with sputum smear-positive pulmon ary tuberculosis were eligible for inclusion; however, in surveillance settings where all tuberculosis cases undergo testing by culture, all culture-positive cases were included irrespective of smear result. In the context of surveys, sample sizes were based on all new smear-positive cases notifi ed in the previous year and the estimated proportion of rifampicin resistance in this population. In most survey settings, previously treated cases were included during the period of intake for new cases, although some countries developed a separate sample size for these cases, and other countries included all cases during the calendar year.
All subcategories of retreatment cases were included: relapse, return after default, and return after failure (ie, patients who were still sputum smear-positive after 5 months of treatment). Countries were encouraged to disaggregate drug resistance data by subcategory of retreatment. Each sample was increased by 15-20% to account for contamination, no culture growth, or loss. One isolate was examined per tuberculosis case. Rechecking of patient treatment history through verifi cation of medical records and patient re-interview was recommended to reduce the possibility of misclassifi cation. Extent and quality rechecking is requested, but not verifi ed by WHO.
Drug susceptibility tests were done by use of the indirect proportion method on Lowenstein-Jensen medium, 8 the absolute concentration method, the resistance ratio method, 9 or the radiometric BACTEC 460 or MGIT 960 methods. 10, 11 Species other than Mycobact erium tuberculosis were excluded from analysis. Quality assurance was undertaken by the supranational reference laboratories by sending a panel of isolates before the implementation of the survey and later by re-checking a percentage of isolates from patients included in the survey.
Statistical analysis
Aggregate data reported from settings were entered into a database built with Microsoft Access software. All the data were re-checked, and all data fi les and epidemiological profi les were returned to countries for verifi cation. Summary analyses were done in Stata (version 9.0). For geographical settings that reported more than one data point since the third report, only the latest data point was used for the estimation of point prevalence. All tests of signifi cance were two-tailed and the alpha error was kept at the 0·05 level in all inference procedures. 95% CIs were calculated around the proportions and the means. Trend analysis was done for geographical settings that reported more than two data points since the beginning of the project. Statistical signifi cance of trends was determined through logistic regression. The association between HIV and drugresistant tuberculosis was assessed by calculation of an odds ratio to compare proportion of drug resistance in HIV-positive patients with tuberculosis with the proportion in HIV-negative patients with tuberculosis. Fisher's exact test was used to determine statistical signifi cance. For analysis of resistance to second-line antituberculosis drugs, the denominator used was MDR isolates tested for resistance to at least one fl uoroquinolone and one injectable second-line antituberculosis drug (needed to defi ne XDR tuberculosis 12 ); for this analysis, MDR-tuberculosis and XDRtuberculosis cases were not diff erentiated by history of previous treatment.
On the basis of drug resistance data reported from 115 countries and territories, we estimated the proportion of MDR tuberculosis in new, previously treated, and combined tuberculosis cases for a further 70 countries and developed a global estimate of incident MDRtuberculosis cases. 5 The estimated number of new tuberculosis cases by country was used to calculate the number of MDR-tuberculosis cases that occurred in new cases. To estimate the number of previously treated cases, we multiplied the ratio of notifi ed previously treated cases to notifi ed new cases in 2006 by the total number of new cases estimated to have occurred in the same year for each country; therefore, the total number of estimated cases includes estimated re-treatment cases. Estimates were developed by use of a logistic regression model described in detail elsewhere. 13, 14 Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had access to all data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The fourth round of the Global Project includes data from 83 countries and territories that provided at least one data point since 2002. Two settings in India completed drug resistance surveys in 2001. We have reported these data in the tables; however, they have been excluded from the analyses. Worldwide, 90 726 tubercu losis cases (consisting of new cases, previously treated cases, and those with an unknown history of previous treatment) were tested for antituberculosis drug resistance. Nine countries provided data that did not diff erentiate between new and previously treated cases.
The median number of cases tested per setting was 553, ranging from fi ve cases in New Caledonia (all with unknown history of previous treatment) to 4350 in Hong Kong (3271 new cases, 163 previously treated, and 916 with unknown history of previous treatment), 4800 in the UK (3428 new cases, 271 previously treated, and 1101 with unknown history of previous treatment), and 10 584 in the USA (all with unknown history of previous treatment).
75 countries and territories provided data on drug resistance in new cases of tuberculosis (table 1). The proportion of new tuberculosis cases with resistance to any drug ranged from 0% (Iceland) to 56·3% (Baku, Azerbaijan), with a median value of 11·1% (IQR 7·0-22·3). The prevalence of resistance to any drug was higher than 30% in 13 settings. A median of 6·7% (IQR 4·2-11·6) of new tuberculosis cases in the surveyed countries were isoniazid resistant. 17 settings reported a prevalence of resistance to isoniazid higher than 15%, 14 of which were located in the former Soviet Union or China. The median prevalence of MDR tuberculosis in new tuberculosis cases was 1·6% (IQR 0·6-3·9), ranging from 0% in eight countries with low tuberculosis prevalence to 19·4% in Moldova (Republic of Moldova) and 22·3% in Baku, Azerbaijan. The prevalence of multidrug resistance in new cases of tuberculosis was higher than 6% in 15 settings. 12 of these settings were in countries of the former Soviet Union, two were provinces in China, and one was Northern Mariana Islands (however, only two cases of MDR tuberculosis were reported in this country; table 1, fi gure). The two settings in India with drug resistance surveys completed in 2001 that were excluded from the analysis had a prevalence of multidrug resistance among new tuberculosis cases similar to that reported elsewhere in the country in subsequent years.
68 countries and territories provided data on drug resistance in previously treated cases of tuberculosis (table 2). The median prevalence of resistance to any drug in previously treated cases was 25·1% (IQR 6·0-46·3). No drug resistance was reported in Iceland, Israel, and Norway, where previously treated patients numbered eight or fewer. By contrast, resistance to any drug was reported in 84·4% of previously treated tuberculosis cases in Baku, Azerbaijan, and 85·9% of cases in Tashkent, Uzbekistan. The prevalence of resistance to any drug was 50% or higher in 16 settings. The median prevalence of MDR tuberculosis in previously treated tuberculosis cases was 11·7% (IQR 4·9-20·9). Six countries reported no patients with MDR tuberculosis, whereas 55·8% of patients in Baku, Azerbaijan, and 60·0% in Tashkent, Uzbekistan, had MDR tuberculosis. In 17 settings, more than 25% of previously treated patients had MDR tuberculosis. Nine of these settings were in countries of the former Soviet Union.
The global estimated number of incident MDRtuberculosis cases in 2006 was 489 139, which was 4·8% of the total number of estimated incident tuberculosis cases in 185 countries (10 192 [1] [2] [3] [4] . In most high-resource countries with low prevalence of tuberculosis, such as the UK, France, and Germany, trends in MDR tuberculosis were stable, and the absolute numbers of MDR tuberculosis were low. Both Peru and South Korea (Republic of Korea) reported increases in the prevalence of multidrug resistance in new cases, but at the same time showed steady declines in tuberculosis notifi cation rates followed by a recent plateau. In countries of the former Soviet Union, where the prevalence of MDR tuberculosis is the highest, there were two scenarios: in the Baltic region, Estonia and Latvia showed stable trends in the prevalence of MDR tuberculosis in new cases, whereas Lithuania showed a slow but signifi cant increase (p=0·012). All three countries showed a decreasing tuberculosis notifi cation rate (5-8% reduction per year). In Orel Oblast and Tomsk Oblast in Russia (Russian Federation), the prevalence of MDR tuberculosis in new cases increased (p=0·001 and p=0·006, respectively) as did the absolute number of MDR tuberculosis cases. Tuberculosis notifi cation rates fell in both regions but at a slower rate (1-3% reduction per year) than in the Baltic countries. Thailand and Nepal showed stable trends in the prevalence of MDR tuberculosis in both new and all tuberculosis cases. 27 countries or territories and two settings in Spain reported routine surveillance data on XDR tuberculosis and nine countries and one setting in Spain reported data from periodic surveys. Most countries that reported 
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Bosnia and Herzegovina, 2005 1·1-2·0) . In both countries, resistance to any tuberculosis drug was also signifi cantly higher in HIV-positive patients than in HIV-negative patients (Latvia OR 1·5, 1·1-2·1; Donetsk Oblast OR 1·4, 1·1-1·8). However, in Latvia, patients categorised as HIV negative included those with unknown HIV status as well as those who had tested negative. In this country, the proportion of tuberculosis cases that were MDR in patients with HIV was shown to be stable over time.
Discussion
Data from our global survey show regional and national variation in the magnitude and trends in drug-resistant tuberculosis. Countries of the former Soviet Union, followed by some provinces of China, reported the highest prevalence of resistance, while the eastern Mediterranean region and southeast Asia reported prevalence of resistance on par with estimated global averages. The data presented here show that of the half a million MDRtuberculosis cases estimated to have emerged in 2006, 50% were in India and China alone, and 27 countries account for 86% of the world's MDR-tuberculosis burden. Countries in the Americas, western and central Europe, and Africa reported the lowest prevalences of MDR tuberculosis. Outliers were identifi ed in all regions, suggesting that prevalence of MDR tuberculosis is linked to performance of national tuberculosis control programmes. Although the magnitude and trends in MDR tuberculosis are epidemiologically important to monitor, the estimation of the burden of disease is programmatically relevant in shaping policies for screening and treatment.
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Figure: Distribution of multidrug-resistant tuberculosis among new cases, 1994-2007
Subnational coverage in China, India, Indonesia, and Russia. Source: WHO, 2008. 5 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Most settings that provided three or more data points between 1994 and 2007 were those with low tuberculosis prevalence and showed stable trends of resistance with low absolute numbers of MDR tuberculosis. Of these settings, however, the USA and Hong Kong-both with strong political and fi nancial commitment to tuberculosis control-reported substantial reductions in the prevalence and case load of MDR tuberculosis, with a faster reduction in MDR tuberculosis than in all forms of tuberculosis. 5 Russia, Peru, and South Korea reported increasing trends in the prevalence and estimated incidence of MDR tuberculosis. The specifi c reasons behind these trends, particularly in South Korea and Peru-two countries with long-term implementation of DOTS-need to be further explored.
Method
The countries of the former Soviet Union are facing a serious and widespread epidemic with the highest prevalence of MDR tuberculosis ever reported in 13 years of global data collection. Almost half of all tuberculosis cases in countries of the former Soviet Union are resistant to at least one drug and one in fi ve cases are MDR. In this region, MDR-tuberculosis cases have more extensive resistance patterns and the highest prevalence of XDR tuberculosis. Trend data from the Baltic countries probably represent the best scenario for this region, with the prevalence of MDR tuberculosis in new cases remaining stable and tuberculosis notifi cation rates declining. These fi ndings are possibly a result of political commitment and long-term investment in tuberculosis control, optimum management of susceptible and drug-resistant tuberculosis cases, and an improving socioeconomic situation. By contrast, the data reported from two Russian oblasts with well-performing tuberculosis control programmes (implementing the WHO recommended strategy to control tuberculosis and with decreasing tuberculosis notifi cation rates) show an alarming situation with increases in both absolute number and prevalence of MDR tuberculosis in new cases and a slowly declining tuberculosis notifi cation rate.
Although the trend data are based on only two of 89 oblasts in Russia, national data-not included in this analysis because of non-conforming methodologyaccord with the fi nding of a nationwide increase in MDR tuberculosis. 15 Tuberculosis control in Russia has been enhanced by new legislation to bring policies in line with the Stop TB Strategy, the expansion of MDR-tuberculosis case management in accordance with international guidelines, and the upgrading of diagnostic services. 16 Nevertheless, eff orts will have to be substantially accelerated and backed by strong political commitment if they are to have an eff ect on the growing epidemic of drug-resistant tuberculosis.
Surveys in eight of 31 provinces and two municipalities in China over a 10-year period show proportions of resistance only second to countries of the former Soviet Union, highlighting a serious drug resistance problem in this region. Trend data are not yet available from provinces in China; however, a nationwide survey currently underway will help to develop a national estimate of MDR tuberculosis.
The widespread reporting of XDR-tuberculosis cases show that they will emerge where second-line drugs are used and cure rates of MDR tuberculosis remain low. The prevalence and distribution of XDR tuberculosis is not well established because of a shortage in laboratory capacity to test for second-line drug resistance, but the data available in this survey show that XDR tuberculosis is currently most severe in countries of the former Soviet Union. With continued use of second-line drugs outside national tuberculosis programmes, the problem of XDR tuberculosis is likely to increase and without appropriate laboratory capacity or new drugs, the world is ill-equipped to manage this emerging crisis. It is important to note that in settings where only one fl uoroquinolone and one injectable drug were tested, XDR-tuberculosis rates might be underestimated.
Although results from fi ve of the countries that provided data for drug resistance stratifi ed by HIV status showed no association between prevalence of MDR tuberculosis and HIV, data from Latvia and Ukraine supported such an association. The data do not allow for determination as to whether the association is related to acquisition or transmission. Nevertheless, the fi ndings have great implications for health-care systems-for example, addressing clinical management of HIV/MDR tuberculosis co-infected patients, as discussed in a recent review paper.
17
Few population-level data for this association exist, which prevents measurement of the global magnitude. To gain a better understanding of the association and to provide best possible clinical management, health systems should expand diagnostic testing and counselling for both diseases. Some sources of bias could exist in this study. First, there is potential for bias in estimation of drug resistance in previously treated cases where either the sample is small or where cluster-sampling based on new cases has been used, although the direction of this bias is impossible to predict. Second, although extent and quality rechecking is requested, but not verifi ed by WHO, misclassifi cation of treatment history can lead to bias. The direction of this bias is unpredictable.
Over the past decade, standardised tuberculosis patient management has been widely implemented and new policies to address HIV/tuberculosis co-infection, MDR tuberculosis, improved laboratory diagnosis, and the engagement of all health-care providers and civil society have been developed, tested, and endorsed. However, the Global Project on Anti-Tuberculosis Drug Resistance has not met some of its initial goals. For example, there are still major geographical areas for which there is no information on the burden of drug-resistant tuberculosis, mainly as a result of inadequate laboratory capacity. In the WHO African Region in particular, only 18 of 46 countries had nationwide drug resistance data and only fi ve reported data since 2002. Furthermore, few trend data from countries with a high burden of tuberculosis are available, and thus the possibility of estimating global trends is limited. If trends are to be determined in high tuberculosis burden countries, surveys need to be easier to implement. Molecular diagnostics hold the greatest promise for scaling up surveillance rapidly, with a substantial advantage over conventional culture and drug susceptibility testing because of the reduced laboratory capacity needed and the transportation of non-infectious material. 18 The understanding of mutations that cause resistance to second-line drugs is currently incomplete; therefore, use of molecular methods alone would only provide information for the two most crucial antituberculosis drugs-ie, isoniazid and rifampicin. However, this disadvantage would be off set by the shortened time needed for screening out the most critical cases (MDR tuberculosis) and phenotypic drug susceptibility testing could be undertaken for all other second-line drugs.
Following an expert review of the Global Project, the existing international guidelines will be revised with new recommendations for laboratory and survey methods. 3, 19 Knowledge of transmission dynamics and acquisition of resistance is crucial for the prioritisation of interventions, but these factors are diffi cult to address in the context of routine surveillance in most settings. Thus, more work is needed in the area of coordinated protocol development.
DOTS is now implemented in 184 countries, 52 resource-limited countries are treating MDR tuberculosis according to WHO guidelines, and most countries are beginning to implement components of the new Stop TB Strategy. The next decade will require accelerated scale-up of the strategy to strengthen basic DOTS activities to ensure quality of treatment to prevent acquisition of resistance, rapid diagnosis of resistant cases, initiation of treatment in accordance with international guidelines to prevent further transmission, and broad application of infection control measures, especially in hospitals and prisons to prevent outbreaks. 20 Currently, the world is far behind reaching the targets for MDR-tuberculosis diagnosis and management set out in the second Global Plan to Stop TB 2006 -2015 Until drug susceptibility testing is implemented routinely for tuberculosis cases as the standard for diagnosis and surveillance, survey mechanisms will continue to be crucial for the determination of trends and the documentation of emergence of further resistance to second-line drugs.
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